Related Experiment Video
Updated: Jun 11, 2026
09:46
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Thrombopoietic agents in immune thrombocytopenia
Waleed Ghanima1, James B Bussel
1Department of Medicine, Østfold Hospital Trust Fredrikstad, Fredrikstad, Norway. Waleed.ghanima@so-hf.no
Seminars in Hematology
|July 13, 2010
Summary
New thrombopoietic agents like romiplostim and eltrombopag offer a novel treatment for immune thrombocytopenia (ITP) by stimulating platelet production. These agents show durable efficacy and acceptable safety in clinical trials for ITP patients.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Immune thrombocytopenia (ITP) involves accelerated platelet destruction and reduced platelet production.
- Traditional ITP treatment focuses on immune suppression.
- Stimulating platelet production offers a new therapeutic avenue.
Purpose of the Study:
- To review second-generation thrombopoietic agents for ITP treatment.
- To evaluate the efficacy and safety of romiplostim and eltrombopag.
- To discuss their role in managing refractory and chronic ITP.
Main Methods:
- Review of randomized controlled trials (RCTs) for romiplostim and eltrombopag.
- Analysis of efficacy data in splenectomized and nonsplenectomized ITP patients.
- Assessment of short- and intermediate-term safety profiles.
Main Results:
- Romiplostim and eltrombopag demonstrated superiority over placebo in RCTs.
- These agents showed durable platelet production during continued treatment.
- An acceptable short- to intermediate-term safety profile was observed.
Conclusions:
- Second-generation thrombopoietic agents are effective new options for ITP.
- They are valuable for refractory ITP and when splenectomy is contraindicated or delayed.
- Further long-term safety data may expand their therapeutic indications.
Related Concept Videos
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...